A new biotechnology company has been formed to develop a needle-free method of delivering vaccines which its backers said Tuesday could improve access to vaccinations for people around the world. Brisbane-based Vaxxas Pty. Ltd. has been launched with A$15 million from investors, led by venture capital firm OneVentures, to continue research and development of a silicone patch known as Nanopatch to deliver vaccine doses. Vaxxas director and OneVentures general partner Paul Kelly said in a statement the investment was an "appreciation of the potential of the technology to revolutionize vaccine delivery worldwide."
